9月30日，伟思医疗举办2025年半年度业绩说明会。会上管理层提到，公司现阶段研发领域发展规划如 下： 磁刺激领域: 聚焦精准神经调控技术研发，依托经颅磁刺激技术平台，深化抑郁症、焦虑症等精神心理 疾病的靶向治疗方案研究；同步推进国际化战略布局，加速盆底磁、塑形磁、经颅磁的海外注册； 电刺激领域: 以临床需求为导向，完成电刺激产品技术的迭代升级，重点开发支持多模块自由组合的智 能电刺激系统，整合生物反馈技术，实现下一代电刺激产品的全面取证上市，拓展其在神经康复、疼痛 管理等领域的应用场景。 电生理和康复机器人等领域：推进脑电结合智能康复机器人备以及康复专用经颅磁联合方案在康复市场 的应用与探索。 激光射频等其他能量源设备领域：扩大皮秒激光的适应证范围，完成皮秒激光产品的规模化量产；推进 脉冲光产品开发进展，构建覆盖面部皮肤治疗的多层次产品矩阵。 有投资者询问公司如何应对康复医疗设备行业增速波动。管理层表示，公司对大康复行业的发展前景充 满信心，相信其未来潜力巨大。康复服务模式也正多元化发展，从医院向社区和家庭延伸，多学科融合 趋势显著，为行业发展注入新动力。 基于此，公司将加大对大康复产业的营销推广和产品营销 ...

Group 1: Xiangyu Medical - The brain-computer interface (BCI) shows clear prospects in rehabilitation, potentially shifting patients from "passive rehabilitation" to "active rehabilitation," reducing labor costs and improving outcomes [1] - The company has an integrated advantage with "BCI technology + proprietary rehabilitation equipment," having obtained registration for two EEG collection devices, with over 20 devices expected to be certified by year-end and nearly 100 by the end of next year [1] - More than 50 large hospitals are currently using the company's equipment, which is expected to contribute to performance in 2025 and significantly enhance performance in 2026 [1] - R&D investment has increased by 38.80% year-on-year, with 117 new patents added, totaling 1,933 patents, including several related to BCI technology [1] - The sales model starts with partnerships with top-tier hospitals to create benchmarks, gradually extending to grassroots levels and eventually entering the home market [1] Group 2: Fenghua Gaoke - In the first half of 2025, the company aims to achieve record highs in product sales and revenue through cost reduction, efficient innovation, and new market development [2] - Automotive electronics sales increased by 39% year-on-year, communications by 22%, industrial control by 21%, and sales to the top ten customers grew by 27% [2] - Supercapacitor sales surged by 138%, with breakthroughs in emerging markets such as computing power, energy storage, intelligent robotics, and low-altitude economy [2] - The company has launched new products including medium and high-voltage MLCCs, MI series alloy resistors, and S series automotive-grade thick film precision resistors, emphasizing high reliability, miniaturization, and high precision [2] - A pricing strategy based on market supply and demand has been implemented to optimize product structure and improve gross margins [2] - The company has initiated a successor plan for talent management and is attracting core technical teams [2] - A "1+2+4+4+N" strategy has been established to promote high-quality development through seven strategic initiatives and various special projects [2]

Group 1 - Chengyitong Control Technology Group Co., Ltd. was established in 2003 and successfully listed on the Shenzhen Stock Exchange in 2015, specializing in intelligent manufacturing system solutions for the biopharmaceutical industry and rehabilitation medical equipment manufacturing [1] - The company has experienced a decline in stock price, with a cumulative drop of -7.15% over four consecutive trading days as of August 21 [1] - In the second quarter of this year, GF Fund's GF Jufeng Mixed A Fund increased its holdings in Chengyitong, achieving a year-to-date return of 22.52%, ranking 1819 out of 4492 in its category [1] Group 2 - The manager of GF Jufeng Mixed A Fund is Su Wenjie, who has a background in industry research and has been with GF Fund since 2015 [3][4] - Su Wenjie has managed various funds, including GF Resource Selection Stock Fund and GF Carbon Neutral Theme Mixed Fund, and has been appointed to manage multiple funds in the coming years [4] - GF Fund Management Co., Ltd. was established in August 2003, with major shareholders including GF Securities Co., Ltd. holding 54.53% [4]

Core Viewpoint - Chengyitong's stock price increased by 7.83% to 24.65 yuan, indicating strong market interest and positive investor sentiment towards the company's strategic initiatives in brain-computer interface technology [1]. Group 1: Company Performance - As of August 13, 2025, Chengyitong's stock closed at 24.65 yuan, up by 1.79 yuan from the previous trading day, with a trading volume of 542,300 shares and a total transaction value of 1.291 billion yuan [1]. - The stock opened at 22.69 yuan, reached a high of 24.87 yuan, and a low of 22.50 yuan during the trading session [1]. Group 2: Business Strategy - Chengyitong operates in the general equipment sector, focusing on smart manufacturing and rehabilitation medical devices [1]. - The company has established a dual-track strategy for brain-computer interface technology, encompassing both invasive and non-invasive approaches [1]. - In the non-invasive sector, Chengyitong is integrating existing rehabilitation devices with brain-computer interface technology to enhance product functionality and promote commercialization [1]. - The company has launched a brain-computer interface biofeedback system aimed at attention detection and training in the education sector [1]. - In the invasive sector, Chengyitong is developing a research verification center and an animal testing center for brain-computer interface technology to strengthen its R&D capabilities [1]. Group 3: Financial Flow - On August 13, 2025, the net inflow of main funds into Chengyitong was 41.04 million yuan, with a cumulative net inflow of 28.52 million yuan over the past five days [2].

Core Viewpoint - Multiple listed companies' controlling shareholders have made commitments not to reduce their holdings, reflecting confidence in the companies' future development and contributing to market stability [1][3]. Group 1: Commitments from Controlling Shareholders - Companies such as Xiangyu Medical, Wanhua Chemical, Guo New Energy, and Jinjiang Hotels have announced commitments from their controlling shareholders to refrain from selling shares for a period of 12 months [1][2]. - Xiangyu Medical's controlling shareholder, Henan Xiangyu Health Industry Management Co., Ltd., and its actual controllers have committed not to reduce their holdings from March 12, 2024, to March 11, 2025 [2]. - Wanhua Chemical's controlling shareholders have also expressed confidence in the company's future and committed to not reducing their holdings for the next 12 months [2]. Group 2: Market Stability and Confidence - The trend of controlling shareholders making long-term commitments not to sell shares is seen as a way to bolster market confidence and protect the interests of all shareholders [3][6]. - The recent increase in commitments from controlling shareholders comes amid a turbulent secondary market, with many companies taking measures to stabilize their stock prices [3][6]. Group 3: Positive Business Performance - Xiangyu Medical reported a significant increase in revenue and net profit for 2023, with total revenue reaching 745 million yuan, a year-on-year increase of 52.46%, and net profit of 230 million yuan, up 82.96% [4]. - Wanhua Chemical achieved total revenue of 175.36 billion yuan in 2023, a 5.92% increase from the previous year, with net profit of 16.81 billion yuan, reflecting a 3.57% growth [5].

Group 1 - The core viewpoint emphasizes the necessity of digital transformation and automation in the manufacturing sector, highlighting the integration of advanced technologies for efficient warehouse management [1][2] - The manufacturing industry is identified as the foundation of the real economy and a key driver for high-quality economic development in the future [1] - Inner Huang County is actively promoting the integration of new-generation information technology with traditional manufacturing, accelerating the transition towards intelligent, high-end, and green manufacturing [1] Group 2 - Small and medium-sized enterprises (SMEs) face challenges in transformation, often feeling unable or unwilling to change; Inner Huang County is addressing this by providing tailored diagnostic services to identify and solve issues [2] - A total of 63 SMEs have received digital transformation consultations, achieving a 93% coverage rate of intelligent application scenarios among regulated enterprises in the county [2] - Significant improvements in operational efficiency are noted, such as the replacement of manual labor with intelligent machines, exemplified by a smart stacking machine that can stack 20 bags of feed per minute with minimal error [2] Group 3 - The ICS689 single-point batching system has improved raw material ratio accuracy from ±0.5% to ±0.3%, with an investment of over 35.5 million yuan in more than 20 intelligent transformation projects expected to enhance production capacity by 25% and reduce energy consumption per ton of feed by 15% [3] - Inner Huang County has successfully collected eight intelligent transformation projects, with five already completed, driving the progress of enterprise automation [3] - Notable achievements in digital transformation include the recognition of Xiangyu Medical's industrial internet platform as a provincial-level platform, enhancing production process optimization and industry chain collaboration [3]

Group 1 - The 15th National Games and the 12th National Paralympic Games have secured sponsorship agreements totaling approximately 232 million yuan, involving 13 sponsors for the National Games and 12 sponsors for the Paralympic Games [1][2] - Anta Group has unveiled the design scheme for the sports uniforms for the National Games, themed "Co-creating Splendor, Shared Prosperity in the Greater Bay Area," incorporating elements of regional collaboration and eco-friendly materials [2][3] - Companies participating in the sponsorship expressed pride and commitment to enhancing the event experience for athletes and spectators, aiming for mutual benefits and brand enhancement through their involvement [2][4] Group 2 - Guangzhou Yikang Medical will provide advanced rehabilitation robots for the Paralympic Games, supporting athlete training and recovery, while also promoting a three-tier rehabilitation ecosystem [3] - Zhuhai Weihong Medical donated 2,000 AED devices to improve emergency medical response during the events, highlighting the importance of portable emergency equipment in saving lives [3] - China People's Insurance Group will offer comprehensive risk coverage for the events, ensuring safety and security through a combination of insurance and risk reduction services [3]

Group 1 - The company Henan Xiangyu Medical Equipment Co., Ltd. has developed a transcranial magnetic-assisted therapy robot that has recently received national medical device registration, allowing it to assist in the treatment of related diseases [1] - The company is accelerating the research and development of key technologies such as embodied intelligent robots and multimodal integration, aiming to create a new highland for innovation and integrated application in the rehabilitation industry [1] - The rehabilitation science city project in Neihuang County is under construction, covering an area of 286 acres and including a high-end traditional Chinese medicine rehabilitation equipment industrial park [1] Group 2 - The Henan Guangyuan New Materials Electronic Materials Industrial Park project has officially commenced production, marking a shift towards high-grade electronic materials for artificial intelligence and high-frequency servers [2] - The project was completed in just over a year, demonstrating effective project management and execution [2] - The local government has implemented measures to stimulate economic growth, including a series of consumption promotion activities and investment expansion initiatives [3]